(Q33397085)

English

Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21902298%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

Europe PubMed Central

Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21902298%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

based on heuristic

inferred from title

dasatinib monohydrate

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21902298%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Paul L McCormack

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21902298%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

1 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21902298%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21902298%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

71

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21902298%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21902298%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1771-1795

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21902298%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Emerging treatments in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Imatinib: a review of its use in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Dasatinib: is it all in the dose?

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib.

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Characterization of cancer stem cells in chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Dasatinib-induced pleural effusions: a lymphatic network disorder?

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Pleural effusions due to dasatinib

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Profound inhibition of antigen-specific T-cell effector functions by dasatinib

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Dasatinib suppresses in vitro natural killer cell cytotoxicity

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Metabolism and disposition of dasatinib after oral administration to humans

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects.

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens!

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Chronic myeloid leukemia: current treatment options

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response o

1 reference

https://api.crossref.org/works/10.2165%2F11207580-000000000-00000

21 January 2018

Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21902298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21902298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacotherapeutic advances in the treatment of acute lymphoblastic leukaemia in adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/21902298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21902298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33397085&oldid=2195321482"